Connection Between GLP-1 Medications and Rare Brain Disorder Identified in Study

FORT WAYNE, Ind. (WOWO) — A recent study has linked popular GLP-1 medications, including Ozempic and Wegovy, to a rare neurological condition known as Wernicke encephalopathy, which arises from severe vitamin B1 deficiency. The findings were published in the journal Clinical Nutrition.

Researchers identified 15 cases of Wernicke encephalopathy among individuals using GLP-1 receptor agonists, such as semaglutide and tirzepatide, also sold as Mounjaro and Zepbound. The condition occurs when the body lacks sufficient thiamine, essential for normal brain function.

The study revealed that many affected patients had significant gastrointestinal issues, including vomiting, appetite loss, and malnutrition. GLP-1 medications can significantly reduce appetite and may induce nausea and vomiting, leading to inadequate nutrient intake.

While the study notes these cases, it does not establish a direct link between GLP-1 medications and Wernicke encephalopathy. The researchers drew on reports from the FDA’s Adverse Event Reporting System, previous medical literature, and records from their medical center. Consequently, the analysis cannot determine how prevalent this condition is among the millions taking GLP-1 drugs or establish a definitive cause-and-effect relationship.

Karthik Achari, a clinician from Chicago who did not participate in the research, emphasized the importance of context. He noted that 15 reported cases is rare when considering the vast number of patients on these medications. However, he acknowledged the seriousness of the condition and the potential underlying mechanisms.

Wernicke encephalopathy can lead to confusion, balance issues, and vision changes, with untreated cases risking permanent neurological damage and even fatality. Achari highlighted that while GLP-1 medications suppress appetite, individuals still require adequate nutrition to meet their body's demands.

Nutritionist Erin Palinski-Wade echoed this sentiment, urging patients to prioritize nutrition and hydration while on GLP-1 medications. Persistent gastrointestinal issues, such as vomiting or diarrhea, could exacerbate risks of dehydration and kidney problems.

Both experts agree patients should not dismiss severe symptoms as mere side effects of medication. Patients experiencing significant nausea, vomiting, or rapid weight loss should consult their healthcare professionals.

The study calls for further investigation to clarify the relationship between GLP-1 medications, nutritional deficiencies, and Wernicke encephalopathy. Patients are advised not to discontinue their prescribed GLP-1 medications without consultation and to monitor their symptoms closely.